The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Ultragenyx (NASDAQ:RARE) is one of the

10 Overlooked Growth Stocks to Buy Now.

Ultragenyx (NASDAQ:RARE) is one of the overlooked growth stocks to buy now. On April 2, Ultragenyx announced that the US FDA accepted the resubmitted BLA for UX111, an investigational AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA). The FDA set a PDUFA action date of September 19 for its decision. If approved, UX111 would become the first available treatment for this rare, fatal genetic disorder, which causes progressive and irreversible neurodegeneration in young children.

The therapy, also known as rebisufligene etisparvovec, is a one-time intravenous infusion designed to deliver a functional copy of the SGSH gene. This addresses the underlying enzyme deficiency responsible for the toxic accumulation of heparan sulfate in the brain. Clinical data included in the BLA, spanning up to 8 years of follow-up, demonstrate a durable treatment effect and clinical improvement compared to the natural progression of the disease. The FDA previously acknowledged the robustness of the neurodevelopmental and biomarker data during the prior review cycle.

Pixabay/Public domain

Sanfilippo syndrome Type A is caused by a lack of the sulfamidase enzyme, leading to a median life expectancy of only 15 years. Ultragenyx’s UX111 received multiple high-level regulatory designations, including Fast Track and Rare Pediatric Disease status. If granted accelerated approval, the therapy will be manufactured at specialized facilities in Ohio and Massachusetts, providing a critical new option for a community currently without any approved disease-modifying treatments.

Ultragenyx (NASDAQ:RARE) is a biotech company that is focused on bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.

While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.